Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722868 | 0.87 | KCNH2 (0.58) | KCNH2ALDH1A1HPGDACHENPSR1 | |
| SCHEMBL1331369 | 0.87 | KCNH2 (0.58) | KCNH2ALDH1A1HPGDACHENPSR1 | |
| SCHEMBL29131330 | 0.83 | MTNR1A (0.42) | KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL17754399 | 0.79 | KCNH2 (0.40) | KCNH2ALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL11432311 | 0.78 | ALDH1A1 (0.39) | KCNH2ALDH1A1NPC1RAB9AACHE | |
| SCHEMBL31248444 | 0.78 | CA2 (0.40) | LTA4HKCNH2NPC1RAB9AACHE | |
| SCHEMBL30810994 | 0.78 | MAOA (0.40) | KCNH2ALDH1A1NPSR1 | |
| SCHEMBL29131265 | 0.78 | MEN1 (0.54) | KCNH2ALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL13969406 | 0.75 | LTA4H (0.55) | LTA4HALDH1A1NPC1HPGDCRHBP | |
| SCHEMBL7886205 | 0.74 | KCNH2 (0.46) | KCNH2ACHENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | DRIVINGFORCE THERAPEUTICS (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180029979-A1 | ISOTHIOCYANATE COMPOUND AND APPLICATION THEREOF | DRIVINGFORCE THERAPEUTICS Co., Ltd. (CN) | 2018-02-01 | — | — | US | disclosed |
| US-20180029979-A1 | ISOTHIOCYANATE COMPOUND AND APPLICATION THEREOF | DRIVINGFORCE THERAPEUTICS Co., Ltd. (CN) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | XPO1, XPOT, XPO4 | LTA4H 4632/4885KCNH2 3539/4885ALDH1A1 3282/4885 |
| US-20180029979-A1 | ISOTHIOCYANATE COMPOUND AND APPLICATION THEREOF | XPO1, XPOT, XPO4 | LTA4H 4431/4885KCNH2 2468/4885ALDH1A1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.